A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine

Mark E. Gerich, J. Antonio Quiros, James P Marcin, Linda Tennyson, Maria Henthorn, Thomas P Prindiville

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: 6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). 6-MP is converted into 6-methylmercaptopurine (6-MMP) or 6-thioguanine nucleotides (6-TGN) intracellularly. Treatment response in IBD patients correlates with 6-TGN levels. This study prospectively evaluated the effect of allopurinol on 6-MP metabolites in adult and pediatric IBD patients. Additionally, we quantified the prevalence of preferential metabolism towards 6-MMP through a retrospective analysis of IBD patients. Methods: Twenty patients (10 adult; 10 pediatric) with evidence of preferential metabolism towards 6-MMP, (6-TGN<250pmol/8X108RBCs and 6-MMP>5000pmol/8X108RBCs) were prospectively treated with allopurinol 100mg daily and up to 100mg of 6-MP. 6-MP dose was adjusted after a 3-week metabolite measurement. Results: The median dose of 6-MP for adults decreased from 100mg daily (range: 37.5-150mg) to 25mg daily (range: 12.5-50mg). The median dose of 6-MP for pediatric patients decreased from 50mg (range: 25-50mg) to 10.7mg (range: 10.7 to 21.4mg). Mean 6-TGN levels in all subjects increased from 197.4 (±59) to 284.8 (±107) pmol/8X108RBCs (p=0.0005). Mean 6-MMP levels in all subjects decreased from a mean of 7719.8 (±4716) to 404.8 (±332) pmol/8x108RBCs (p=0.0004). There were no complications associated with allopurinol therapy. Eighty-eight (30.9%) of 285 IBD patients had evidence of preferential metabolism towards 6-MMP. The proportion of preferential metabolism was equal in adults and pediatric patients. Conclusion: Our results indicate that the addition of allopurinol safely shifts metabolite production in both adult and pediatric IBD patients and that there is a high prevalence of preferential metabolism towards 6-MMP among IBD patients.

Original languageEnglish (US)
Pages (from-to)546-552
Number of pages7
JournalJournal of Crohn's and Colitis
Volume4
Issue number5
DOIs
StatePublished - Nov 2010

Fingerprint

6-Mercaptopurine
Allopurinol
Inflammatory Bowel Diseases
Pediatrics
6-methylthiopurine
Remission Induction
Maintenance

Keywords

  • 6-MMP
  • 6-MP
  • 6-TG
  • Allopurinol
  • IBD
  • Thiopurine
  • TPMT

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. / Gerich, Mark E.; Quiros, J. Antonio; Marcin, James P; Tennyson, Linda; Henthorn, Maria; Prindiville, Thomas P.

In: Journal of Crohn's and Colitis, Vol. 4, No. 5, 11.2010, p. 546-552.

Research output: Contribution to journalArticle

@article{95f58b71fa38461591a975296d431807,
title = "A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine",
abstract = "Background: 6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). 6-MP is converted into 6-methylmercaptopurine (6-MMP) or 6-thioguanine nucleotides (6-TGN) intracellularly. Treatment response in IBD patients correlates with 6-TGN levels. This study prospectively evaluated the effect of allopurinol on 6-MP metabolites in adult and pediatric IBD patients. Additionally, we quantified the prevalence of preferential metabolism towards 6-MMP through a retrospective analysis of IBD patients. Methods: Twenty patients (10 adult; 10 pediatric) with evidence of preferential metabolism towards 6-MMP, (6-TGN<250pmol/8X108RBCs and 6-MMP>5000pmol/8X108RBCs) were prospectively treated with allopurinol 100mg daily and up to 100mg of 6-MP. 6-MP dose was adjusted after a 3-week metabolite measurement. Results: The median dose of 6-MP for adults decreased from 100mg daily (range: 37.5-150mg) to 25mg daily (range: 12.5-50mg). The median dose of 6-MP for pediatric patients decreased from 50mg (range: 25-50mg) to 10.7mg (range: 10.7 to 21.4mg). Mean 6-TGN levels in all subjects increased from 197.4 (±59) to 284.8 (±107) pmol/8X108RBCs (p=0.0005). Mean 6-MMP levels in all subjects decreased from a mean of 7719.8 (±4716) to 404.8 (±332) pmol/8x108RBCs (p=0.0004). There were no complications associated with allopurinol therapy. Eighty-eight (30.9{\%}) of 285 IBD patients had evidence of preferential metabolism towards 6-MMP. The proportion of preferential metabolism was equal in adults and pediatric patients. Conclusion: Our results indicate that the addition of allopurinol safely shifts metabolite production in both adult and pediatric IBD patients and that there is a high prevalence of preferential metabolism towards 6-MMP among IBD patients.",
keywords = "6-MMP, 6-MP, 6-TG, Allopurinol, IBD, Thiopurine, TPMT",
author = "Gerich, {Mark E.} and Quiros, {J. Antonio} and Marcin, {James P} and Linda Tennyson and Maria Henthorn and Prindiville, {Thomas P}",
year = "2010",
month = "11",
doi = "10.1016/j.crohns.2010.03.004",
language = "English (US)",
volume = "4",
pages = "546--552",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine

AU - Gerich, Mark E.

AU - Quiros, J. Antonio

AU - Marcin, James P

AU - Tennyson, Linda

AU - Henthorn, Maria

AU - Prindiville, Thomas P

PY - 2010/11

Y1 - 2010/11

N2 - Background: 6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). 6-MP is converted into 6-methylmercaptopurine (6-MMP) or 6-thioguanine nucleotides (6-TGN) intracellularly. Treatment response in IBD patients correlates with 6-TGN levels. This study prospectively evaluated the effect of allopurinol on 6-MP metabolites in adult and pediatric IBD patients. Additionally, we quantified the prevalence of preferential metabolism towards 6-MMP through a retrospective analysis of IBD patients. Methods: Twenty patients (10 adult; 10 pediatric) with evidence of preferential metabolism towards 6-MMP, (6-TGN<250pmol/8X108RBCs and 6-MMP>5000pmol/8X108RBCs) were prospectively treated with allopurinol 100mg daily and up to 100mg of 6-MP. 6-MP dose was adjusted after a 3-week metabolite measurement. Results: The median dose of 6-MP for adults decreased from 100mg daily (range: 37.5-150mg) to 25mg daily (range: 12.5-50mg). The median dose of 6-MP for pediatric patients decreased from 50mg (range: 25-50mg) to 10.7mg (range: 10.7 to 21.4mg). Mean 6-TGN levels in all subjects increased from 197.4 (±59) to 284.8 (±107) pmol/8X108RBCs (p=0.0005). Mean 6-MMP levels in all subjects decreased from a mean of 7719.8 (±4716) to 404.8 (±332) pmol/8x108RBCs (p=0.0004). There were no complications associated with allopurinol therapy. Eighty-eight (30.9%) of 285 IBD patients had evidence of preferential metabolism towards 6-MMP. The proportion of preferential metabolism was equal in adults and pediatric patients. Conclusion: Our results indicate that the addition of allopurinol safely shifts metabolite production in both adult and pediatric IBD patients and that there is a high prevalence of preferential metabolism towards 6-MMP among IBD patients.

AB - Background: 6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). 6-MP is converted into 6-methylmercaptopurine (6-MMP) or 6-thioguanine nucleotides (6-TGN) intracellularly. Treatment response in IBD patients correlates with 6-TGN levels. This study prospectively evaluated the effect of allopurinol on 6-MP metabolites in adult and pediatric IBD patients. Additionally, we quantified the prevalence of preferential metabolism towards 6-MMP through a retrospective analysis of IBD patients. Methods: Twenty patients (10 adult; 10 pediatric) with evidence of preferential metabolism towards 6-MMP, (6-TGN<250pmol/8X108RBCs and 6-MMP>5000pmol/8X108RBCs) were prospectively treated with allopurinol 100mg daily and up to 100mg of 6-MP. 6-MP dose was adjusted after a 3-week metabolite measurement. Results: The median dose of 6-MP for adults decreased from 100mg daily (range: 37.5-150mg) to 25mg daily (range: 12.5-50mg). The median dose of 6-MP for pediatric patients decreased from 50mg (range: 25-50mg) to 10.7mg (range: 10.7 to 21.4mg). Mean 6-TGN levels in all subjects increased from 197.4 (±59) to 284.8 (±107) pmol/8X108RBCs (p=0.0005). Mean 6-MMP levels in all subjects decreased from a mean of 7719.8 (±4716) to 404.8 (±332) pmol/8x108RBCs (p=0.0004). There were no complications associated with allopurinol therapy. Eighty-eight (30.9%) of 285 IBD patients had evidence of preferential metabolism towards 6-MMP. The proportion of preferential metabolism was equal in adults and pediatric patients. Conclusion: Our results indicate that the addition of allopurinol safely shifts metabolite production in both adult and pediatric IBD patients and that there is a high prevalence of preferential metabolism towards 6-MMP among IBD patients.

KW - 6-MMP

KW - 6-MP

KW - 6-TG

KW - Allopurinol

KW - IBD

KW - Thiopurine

KW - TPMT

UR - http://www.scopus.com/inward/record.url?scp=77958152828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958152828&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2010.03.004

DO - 10.1016/j.crohns.2010.03.004

M3 - Article

C2 - 21122558

AN - SCOPUS:77958152828

VL - 4

SP - 546

EP - 552

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 5

ER -